Safety and tolerability of pirfenidone in asbestosis: a prospective multicenter study
Open Access
- 28 May 2022
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 23 (1) , 1-6
Abstract
Background: Pirfenidone slows down disease progression in idiopathic pulmonary fibrosis (IPF). Recent studies suggest a treatment effect in progressive pulmonary fibrosis other than IPF. However, the safety and effectiveness of pirfenidone in asbestosis patients remain unclear. In this study, we aimed to investigate the safety, tolerability and efficacy of pirfenidone in asbestosis patients with a progressive phenotype. Methods: This was a multicenter prospective study in asbestosis patients with progressive lung function decline. After a 12-week observational period, patients were treated with pirfenidone 801 mg three times a day. Symptoms and adverse events were evaluated weekly and patients completed online patient-reported outcomes measures. At baseline, start of therapy, 12 and 24 weeks, in hospital measurement of lung function and a 6 min walking test were performed. Additionally, patients performed daily home spirometry measurements. Results: In total, 10 patients were included of whom 6 patients (66.7%) experienced any adverse events during the study period. Most frequently reported adverse events were fatigue, rash, anorexia and cough, which mostly occurred intermittently and were reported as not very bothersome. No significant changes in hospital pulmonary function (forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO), 6 min walking test or patient-reported outcomes measures before and after start of pirfenidone were found. Home spirometry demonstrated a FVC decline in 12 weeks before start of pirfenidone, while FVC did not decline during the 24 week treatment phase, but this difference was not statistically significant. Conclusions: Treatment with pirfenidone in asbestosis has an acceptable safety and tolerability profile and home spirometry data suggest this antifibrotic treatment might attenuate FVC decline in progressive asbestosis. Trial registration MEC-2018-1392; EudraCT number: 2018-001781-41Keywords
This publication has 19 references indexed in Scilit:
- Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trialThe Lancet Respiratory Medicine, 2020
- Nintedanib in Progressive Fibrosing Interstitial Lung DiseasesNew England Journal of Medicine, 2019
- The natural course of lung function decline in asbestos exposed subjects with pleural plaques and asbestosisRespiratory Medicine, 2019
- Long-term safety of pirfenidone: results of the prospective, observational PASSPORT studyERJ Open Research, 2018
- Impact of comorbidities and delay in diagnosis in elderly patients with pulmonary hypertensionERJ Open Research, 2018
- Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2017
- Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case–cohort studyEuropean Respiratory Journal, 2017
- Home monitoring improves endpoint efficiency in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2017
- Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trialsEuropean Respiratory Journal, 2015
- Diagnosis and Initial Management of Nonmalignant Diseases Related to AsbestosAmerican Journal of Respiratory and Critical Care Medicine, 2004